BPA #36E79727A0001

Galderma Laboratories Awarded Blanket Purchase Agreement for Dermatological Drugs

This award is a Blanket Purchase Agreement (BPA) granted to Galderma Laboratories, L.P., a leading dermatological pharmaceuticals company. The contract ensures the ongoing procurement of key pharmaceutical products including Tri-Luma, Soolantra, Aklief, and Oracea, which are essential for various medical treatments. The BPA supports healthcare agencies by maintaining a reliable supply of these specialized dermatological medications. The scope involves continuous delivery of these drugs over a multi-year period, reflecting a long-term commitment. The contract was awarded as a continuation under an existing Federal Supply Schedule (FSS) contract vehicle, demonstrating Galderma's established performance and trusted relationship with federal healthcare providers. This agreement follows a competitive process and builds upon a prior FSS contract awarded to Galderma, which facilitated broader pharmaceutical procurement and ensured steady drug availability for the Department of Veterans Affairs and other agencies. The performance period extends for one year initially, with potential extensions. This arrangement is significant as it sustains critical healthcare initiatives by guaranteeing access to vital pharmaceuticals through a streamlined federal contracting mechanism.

Description

BPA FOR TRI-LUMA, SOOLANTRA, AKLIEF, AND ORACEA

View original record